GlassScriptPhysician profile
Kim Dankha
NPI 1942965504
$2,376.64
in general payments reported to CMS, 2019-2025
16 companies · $753 in 2025
The $753 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $539 · 2023: $476 · 2024: $609 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,805 · Honoraria: $32.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,804.71 |
| Honoraria | $32.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $855.74 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Tarsus Pharmaceuticals, INC. | $256.50 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $218.45 | 2022-2025 | Kxl System (Not Refurbished), Kxl1b-Ce-Marked Kxlsystem, Idosetr |
| Alcon Vision LLC | $189.77 | 2022-2025 | Tryptyr, Rocklatan |
| Sun Pharmaceutical Industries INC. | $151.76 | 2022 | |
| Novartis Pharmaceuticals Corporation | $133.33 | 2022-2023 | |
| Oyster Point Pharma, INC. | $96.59 | 2022-2024 | Tyrvaya, Ryzumvi |
| Harrow Eye, LLC | $73.15 | 2025 | Vevye |
| Rxsight INC | $69.52 | 2022-2025 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Biotissue Holdings INC. | $64.18 | 2024 | |
| Abbvie INC. | $60.71 | 2023-2024 | Alphagan P, Lumigan |
| Mallinckrodt Hospital Products INC. | $59.62 | 2025 | Acthar |
| Amgen INC. | $54.10 | 2024-2025 | Tepezza |
| Dompe US, INC. | $51.61 | 2024-2025 | Oxervate |
| Carl Zeiss Meditec USA, INC. | $22.04 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $19.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Dankha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.